TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Protein arginine methyltransferase (PRMT) 4, also known as CARM1, is implicated in various biological processes and cancer.
• Overexpression of PRMT4 in cancers highlights its potential as a therapeutic target.
• Selective PRMT4 inhibitors are crucial for understanding its biological roles and therapeutic validity.

Purpose of the Study:

• To discover and characterize a potent, selective, and cell-active chemical probe for human PRMT4.
• To elucidate the molecular mechanisms and therapeutic potential of PRMT4 inhibition.

Main Methods:

• Discovery of TP-064, a novel chemical probe for PRMT4.
• Co-crystal structure determination of TP-064 with PRMT4.
• In vitro enzymatic assays to assess PRMT4 methyltransferase activity and substrate inhibition.
• Cell-based assays to evaluate TP-064's effect on cell proliferation and cell cycle progression.

Main Results:

• TP-064 demonstrated high potency (IC50 < 10 nM) and selectivity for PRMT4 inhibition.
• TP-064 effectively reduced arginine dimethylation of PRMT4 substrates BAF155 and MED12.
• TP-064 treatment inhibited proliferation and induced G1 cell cycle arrest in a subset of multiple myeloma cell lines.

Conclusions:

• TP-064 is a valuable chemical probe for studying PRMT4 biology.
• PRMT4 inhibition shows therapeutic potential in multiple myeloma.
• TP-064 and its control (TP-064N) will facilitate further research into PRMT4-driven processes and cancer therapy.